Goldman Sachs Group Inc. decreased its position in Fluidigm Corporation (NASDAQ:FLDM) by 0.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 145,063 shares of the medical research company’s stock after selling 603 shares during the period. Goldman Sachs Group Inc.’s holdings in Fluidigm Corporation were worth $825,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Paloma Partners Management Co boosted its stake in Fluidigm Corporation by 319.4% in the first quarter. Paloma Partners Management Co now owns 125,000 shares of the medical research company’s stock worth $711,000 after buying an additional 95,193 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Fluidigm Corporation by 5.6% in the first quarter. Renaissance Technologies LLC now owns 476,400 shares of the medical research company’s stock worth $2,711,000 after buying an additional 25,100 shares during the last quarter. Geode Capital Management LLC boosted its stake in Fluidigm Corporation by 1.5% in the first quarter. Geode Capital Management LLC now owns 218,321 shares of the medical research company’s stock worth $1,242,000 after buying an additional 3,311 shares during the last quarter. Vanguard Group Inc. boosted its stake in Fluidigm Corporation by 1.7% in the first quarter. Vanguard Group Inc. now owns 1,181,883 shares of the medical research company’s stock worth $6,725,000 after buying an additional 19,669 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Fluidigm Corporation by 2.4% in the first quarter. Wellington Management Group LLP now owns 630,277 shares of the medical research company’s stock worth $3,587,000 after buying an additional 14,814 shares during the last quarter. Institutional investors own 91.41% of the company’s stock.
Fluidigm Corporation (FLDM) traded down 3.60% during midday trading on Tuesday, hitting $3.48. The stock had a trading volume of 41,129 shares. The firm’s market cap is $102.36 million. The firm has a 50 day moving average of $3.74 and a 200 day moving average of $4.91. Fluidigm Corporation has a 52 week low of $2.52 and a 52 week high of $9.65.
Fluidigm Corporation (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $23.50 million. During the same period last year, the firm earned ($0.63) EPS. The company’s revenue for the quarter was down 15.2% on a year-over-year basis. Equities research analysts predict that Fluidigm Corporation will post ($2.19) EPS for the current year.
A number of equities research analysts have recently commented on the company. ValuEngine cut Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research upgraded Fluidigm Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 1st.
In related news, insider Steven Mcphail acquired 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was purchased at an average cost of $3.00 per share, for a total transaction of $60,000.00. Following the transaction, the insider now directly owns 27,842 shares of the company’s stock, valued at approximately $83,526. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Stephen Christopher Linthwaite acquired 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The shares were bought at an average price of $2.66 per share, with a total value of $119,700.00. Following the completion of the transaction, the chief executive officer now directly owns 106,977 shares in the company, valued at $284,558.82. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,105,573 shares of company stock valued at $13,494,381. Insiders own 4.70% of the company’s stock.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Corporation (NASDAQ:FLDM).
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
